We are live on ! Find out more

EDVA

Endovia Health Sciences, Inc.

EDVA

Market cap $2.46M

0.3834 USD

-0.0348

8.32%

At close Updated Aug 26, 12:54 PM EDT

1 day

-8.32%

5 days

-5.08%

1 month

16.15%

3 months

-42.95%

6 months

-82.25%

Year to date

-87.05%

1 year

-94.82%

5 years

-99.9%

10 years

-99.93%

About: Endovia Health Sciences Inc is building a diversified cannabinoid health sciences platform through pharmaceutical innovation, strategic partnerships and disciplined execution. Endovia acquires, develops and commercializes differentiated cannabinoid health technologies across pharmaceutical, veterinary and consumer wellness markets. Endovia's product begins with CannEpil, a cannabinoid pharmaceutical asset, and extends into veterinary development and consumer wellness as the pipeline expands.

Employees: 3

Consumer Staples Beverages - Non-Alcoholic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program

FORT LAUDERDALE, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Endovia Health Sciences, Inc. (NYSE American: EDVA), formerly Splash Beverage Group, Inc. (NYSE American: SBEV) ("Endovia Health" or the "Company") announced that the U.S. Food and Drug Administration's Center for Veterinary Medicine has established Investigational New Animal Drug (INAD) File No.

Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program

Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday

FORT LAUDERDALE, Fla., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (the “Company”) today announced that its corporate name will change to Endovia Health Sciences, Inc., and its common stock will begin trading on the NYSE American under the new ticker symbol “EDVA” effective at market open at 9:30 a.m.

Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday

Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences

FORT LAUDERDALE, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today reported financial results for the second quarter ended June 30, 2026, and provided an update on the Company's ongoing strategic transformation toward Endovia Health Sciences.

Splash Beverage Reports Second Quarter 2026 Results and Highlights Strategic Transformation Toward Endovia Health Sciences

Splash Beverage Group to Rebrand as Endovia Health Sciences

FORT LAUDERDALE, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (the "Company") today announced its intention to change its corporate name to Endovia Health Sciences, Inc., effective August 21, 2026.

Splash Beverage Group to Rebrand as Endovia Health Sciences

Splash Beverage Group Partners with Veteran Cannabinoid Drug-Development Team to Advance CannEpil® Through FDA Veterinary Pathway

Collaboration with Lupvindol Biosciences will initially target companion-animal oncology and chronic pain management Splash retains ownership of resulting data, intellectual property and commercialization rights FORT LAUDERDALE, Fla., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) (“Splash” or the “Company”) today announced that it has entered into a strategic development and collaboration agreement with Lupvindol Biosciences Ltd.

Splash Beverage Group Partners with Veteran Cannabinoid Drug-Development Team to Advance CannEpil® Through FDA Veterinary Pathway

Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program

Splash expands its exclusive global license for CannEpil® to include veterinary applications, creating a second regulated pharmaceutical development platfo

Splash Beverage Group Expands CannEpil® Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program

Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation

SPLASH announces significant actions designed to strengthen the Company's financial position and advance its previously announced NYSE compliance plan.

Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation

Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation

FORT LAUDERDALE, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) ("Splash," "Splash Beverage" or the "Company") today announced that NYSE American has accepted the Company's plan to regain compliance with the Exchange's continued listing standards and has granted the Company a compliance period through January 29, 2027.

Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation

Splash Beverage Group Acquires Exclusive Global Rights to CannEpil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential

$SBEV announces licensing agreement with Argent BioPharma for CannEpil®, a proprietary, cannabinoid-based therapeutic for the treatment of epilepsy (DRE)

Splash Beverage Group Acquires Exclusive Global Rights to CannEpil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

FORT LAUDERDALE, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Splash Beverage Group, Inc. (NYSE American: SBEV) today announced the completion of a CDN$300,000 strategic investment in Avicanna Inc. (TSX: AVCN), a commercial-stage cannabinoid-based biopharmaceutical company focused on clinical research, patient care, and developing pharmaceutical products.

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

See News Rankings

Price charts implemented using Lightweight Charts™